Repository logo
 

Effects of a reduced dose of Stavudine on the incidence and severity of peripheral neuropathy in HIV-infected adults in South Africa.

Simple item page
dc.contributor.authorPahuja, Meera.
dc.contributor.authorGrobler, Anna Christina.
dc.contributor.authorGlesby, Marshall J.
dc.contributor.authorKarim, Farina.
dc.contributor.authorParker, Gary.
dc.contributor.authorGumede, Sizwe.
dc.contributor.authorNaidoo, Kogieleum.
dc.date.accessioned2013-06-25T07:15:18Z
dc.date.available2013-06-25T07:15:18Z
dc.date.created2011
dc.date.issued2011
dc.description.abstractBACKGROUND—Although recent WHO guidelines recommend withdrawing stavudine (d4T) from first-line ART therapy, it remains commonly used in resource-constrained settings. In 2006, WHO recommended decreasing the dose of d4T from 40mg to 30mg to mitigate toxicities. We compared the incidence and severity of peripheral neuropathy (PN) by d4T dose in a retrospective cohort study. METHODS—Patients’ charts from an ART-naïve population at a rural clinic in KZN, South Africa were retrospectively reviewed for signs and symptoms of incident PN and were graded for severity using the DAIDs scale. Patients enrolled prior to the WHO guideline change were enrolled if they were on d4T 40mg for at least 6 months. After the guideline change all patients were initiated on d4T 30mg. RESULTS—A total of 475 patients were analyzed; 235 in the 40mg cohort (152.7 person-years [py]) and 240 in the 30mg cohort (244.7py). Incidence of peripheral neuropathy was 90.4/100 py (95% CI:75.9–106.8) in the 40mg cohort versus 40.5/100py (95% CI:32.9–49.3) in the 30mg group (incidence rate ratio [IRR]=0.45, p<0.0001). There was no difference in proportion of severe peripheral neuropathy cases (grade 3/4) between the cohorts; 8.3% in the 40mg group and 8.9% in the 30mg group (p=1.0). In a multivariate analysis risk of peripheral neuropathy was associated with increasing age (HR=1.65 95% CI:1.24–2.19), 40 mg dose (HR=2.1, 95% CI:1.61–2.74) and concurrent tuberculosis therapy (HR= 1.41 95% CI:1.06–1.87). CONCLUSION—Incidence of peripheral neuropathy in the 40mg cohort was extremely high and though lower in the 30mg cohort, the rate was nonetheless unacceptably high.en
dc.identifier.citationPahuja, M. et al. 2012. Effects of a reduced dose of Stavudine on the incidence and severity of peripheral neuropathy in HIV-infected adults in South Africa. Antivir Ther. 17(4) pp. 737–743.en
dc.identifier.issn1359-6535
dc.identifier.urihttp://dx.doi.org/10.3851/IMP2087en
dc.identifier.urihttp://hdl.handle.net/10413/9185
dc.language.isoenen
dc.publisherInternational Medical Press.en
dc.subjectHIV infections--Treatment.en
dc.subjectHIV infections--Drug therapy--South Africa.en
dc.subject.otherStavudine (d4T)en
dc.titleEffects of a reduced dose of Stavudine on the incidence and severity of peripheral neuropathy in HIV-infected adults in South Africa.en
dc.typePeer reviewed journal articleen

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Pahuja_Meera_2012.pdf
Size:
568.17 KB
Format:
Adobe Portable Document Format
Description:
Journal article
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.64 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Research papers (Caprisa)